Cargando…

HE4 and eIF3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction

For recurrent ovarian cancer (ROC), secondary cytoreductive surgery (SCS) is recommended as one optional treatment. However, little is known about the expression and clinical significance of biomarkers during SCS. Human epididymis protein 4 (HE4) is a clinical biomarker for ovarian cancer. Eukaryoti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Chen-Hui, Zhao, Min, Chen, Xiao-Yan, Shahabi, Shohreh, Qiang, Wenan, Zeng, Liang, Wang, Jing, Zhou, Hong-Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036880/ https://www.ncbi.nlm.nih.gov/pubmed/30026845 http://dx.doi.org/10.7150/jca.25184

Ejemplares similares

Increased HE4 mRNA Expression Correlates with High Level Of eIF3a mRNA And Better Survival in Women with Epithelial Ovarian Cancer
por: Luo, Chen-Hui, et al.
Publicado: (2018)

Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review
por: Chase, Dana M, et al.
Publicado: (2023)

Secondary surgical cytoreduction needs to be assessed taking into account surgical technique, completeness of cytoreduction, and extent of disease
por: Segura-Sampedro, Juan José, et al.
Publicado: (2020)

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer
por: Certelli, Camilla, et al.
Publicado: (2023)

Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy
por: Liu, Yuan-Yuan, et al.
Publicado: (2022)

Role of aggressive surgical cytoreduction in advanced ovarian cancer
por: Chang, Suk-Joon, et al.
Publicado: (2015)

Trends in extent of surgical cytoreduction for patients with ovarian cancer
por: Wong, Deanna H., et al.
Publicado: (2021)

The current role of secondary cytoreductive surgery for recurrent ovarian cancer
por: de Bree, Eelco, et al.
Publicado: (2022)

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients
por: Saffarieh, Elham, et al.
Publicado: (2022)

Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
por: Jeong, Soo Young, et al.
Publicado: (2019)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer
por: Bogani, Giorgio, et al.
Publicado: (2018)

Simplified Selection Criteria for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2022)

CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery
por: Wang, Fang, et al.
Publicado: (2013)

When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place?
por: Martinek, Igor E., et al.
Publicado: (2010)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013)

Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection
por: Onda, T, et al.
Publicado: (2005)

Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
por: Zang, Rongyu, et al.
Publicado: (2019)

Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer
por: McNamara, Blair, et al.
Publicado: (2021)

Development and External Validation of a Novel Model for Predicting Postsurgical Recurrence and Overall Survival After Cytoreductive R0 Resection of Epithelial Ovarian Cancer
por: Li, Qiaqia, et al.
Publicado: (2022)

Impact of insurance status on overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
por: Chokshi, Ravi J., et al.
Publicado: (2020)

Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
por: Fotopoulou, C, et al.
Publicado: (2013)

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
por: Zang, R Y, et al.
Publicado: (2011)

The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis
por: Ding, Ting, et al.
Publicado: (2021)

Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review
por: Conte, Carmine, et al.
Publicado: (2021)

Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
por: Jiang, Caixia, et al.
Publicado: (2021)

A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses
por: Bogani, Giorgio, et al.
Publicado: (2018)

Severe pulmonary complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are common and contribute to decreased overall survival
por: Sand, Olivia, et al.
Publicado: (2021)

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers
por: Seagle, Brandon-Luke L., et al.
Publicado: (2015)

Splenectomy during cytoreductive surgery in epithelial ovarian cancer
por: Sun, Hengzi, et al.
Publicado: (2018)

Laparoscopic Cytoreduction for Primary Advanced Ovarian Cancer
por: Fanning, James, et al.
Publicado: (2010)

Overall survival and morbidity are not associated with advanced age for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a single centre experience
por: Cheng, Ernest, et al.
Publicado: (2023)

Race and Ethnicity Impacts Overall Survival of Patients with Appendiceal Cancer Who Undergo Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
por: Freudenberger, Devon C., et al.
Publicado: (2023)

Secondary surgical cytoreduction of thoracic metastasis in a high grade serous ovarian carcinoma by video-assisted thoracoscopic surgery (VATS) in 10 steps
por: Hermoza, Alejandro Delfos, et al.
Publicado: (2023)

Explainable Artificial Intelligence for Prediction of Complete Surgical Cytoreduction in Advanced-Stage Epithelial Ovarian Cancer
por: Laios, Alexandros, et al.
Publicado: (2022)

Development and validation of a nomogram to predict cancer-specific survival of mucinous epithelial ovarian cancer after cytoreductive surgery
por: Ma, Guanchen, et al.
Publicado: (2023)

The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?
por: Coleman, Robert L.
Publicado: (2020)

Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma
por: Kim, Se Ik, et al.
Publicado: (2022)

Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study
por: Feng, Li-yuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kmssqe3g0b67uomsrce0srp2eq